Aldeyra Therapeutics, Inc, a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone781-761-4904
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date3/13/2020 (Estimated)
OptionableOptionable
Aldeyra Therapeutics (NASDAQ:ALDX) Frequently Asked Questions
What is Aldeyra Therapeutics' stock symbol?
Aldeyra Therapeutics trades on the NASDAQ under the ticker symbol "ALDX."
How were Aldeyra Therapeutics' earnings last quarter?
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) released its quarterly earnings data on Thursday, November, 7th. The biotechnology company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.55) by $0.14. View Aldeyra Therapeutics' Earnings History.
When is Aldeyra Therapeutics' next earnings date?
What price target have analysts set for ALDX?
3 brokers have issued twelve-month price targets for Aldeyra Therapeutics' stock. Their forecasts range from $20.00 to $38.00. On average, they anticipate Aldeyra Therapeutics' stock price to reach $30.33 in the next twelve months. This suggests a possible upside of 417.6% from the stock's current price. View Analyst Price Targets for Aldeyra Therapeutics.
What is the consensus analysts' recommendation for Aldeyra Therapeutics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aldeyra Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aldeyra Therapeutics.
Has Aldeyra Therapeutics been receiving favorable news coverage?
Media headlines about ALDX stock have been trending extremely negative this week, according to InfoTrie. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Aldeyra Therapeutics earned a news impact score of -4.6 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Aldeyra Therapeutics.
Are investors shorting Aldeyra Therapeutics?
Aldeyra Therapeutics saw a drop in short interest in October. As of October 15th, there was short interest totalling 854,900 shares, a drop of 10.9% from the September 15th total of 959,300 shares. Based on an average trading volume of 190,200 shares, the days-to-cover ratio is currently 4.5 days. Approximately 3.6% of the company's shares are short sold. View Aldeyra Therapeutics' Current Options Chain.
Who are some of Aldeyra Therapeutics' key competitors?
Some companies that are related to Aldeyra Therapeutics include ANI Pharmaceuticals (ANIP), Collegium Pharmaceutical (COLL), Flexion Therapeutics (FLXN), Homology Medicines (FIXX), Emisphere Technologies (EMIS), Viking Therapeutics (VKTX), Akero Therapeutics (AKRO), DiaMedica Therapeutics (DMCAF), BioDelivery Sciences International (BDSI), Retrophin (RTRX), Myovant Sciences (MYOV), Advanz Pharma (CXRXF), Urogen Pharma (URGN), XBiotech (XBIT) and Aprea Therapeutics (APRE).
What other stocks do shareholders of Aldeyra Therapeutics own?
Who are Aldeyra Therapeutics' key executives?
Aldeyra Therapeutics' management team includes the folowing people:
- Dr. Todd C. Brady, Chief Exec. Officer, Pres and Director (Age 46)
- Mr. Stephen J. Tulipano CPA, MBA, Chief Financial Officer and Treasurer (Age 59)
- Dr. David J. Clark M.D., M.R.C.P., A.F.P.M., Chief Medical Officer (Age 53)
- Ms. Mary Taylor M.P.H., Sr. VP of Regulatory Affairs (Age 59)
Who are Aldeyra Therapeutics' major shareholders?
Aldeyra Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Hikari Power Ltd (0.29%), Russell Investments Group Ltd. (0.21%), Strs Ohio (0.11%) and Meeder Asset Management Inc. (0.04%). Company insiders that own Aldeyra Therapeutics stock include Ben Bronstein, David Mcmullin, Jesse I Treu, Joshua Reed, Richard Douglas and Todd C Brady. View Institutional Ownership Trends for Aldeyra Therapeutics.
Which institutional investors are selling Aldeyra Therapeutics stock?
Which institutional investors are buying Aldeyra Therapeutics stock?
ALDX stock was purchased by a variety of institutional investors in the last quarter, including Hikari Power Ltd and Meeder Asset Management Inc.. Company insiders that have bought Aldeyra Therapeutics stock in the last two years include Ben Bronstein, David Mcmullin, Joshua Reed, Richard Douglas and Todd C Brady. View Insider Buying and Selling for Aldeyra Therapeutics.
How do I buy shares of Aldeyra Therapeutics?
Shares of ALDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Aldeyra Therapeutics' stock price today?
One share of ALDX stock can currently be purchased for approximately $5.86.
How big of a company is Aldeyra Therapeutics?
What is Aldeyra Therapeutics' official website?
How can I contact Aldeyra Therapeutics?
Aldeyra Therapeutics' mailing address is 131 HARTWELL AVENUE SUITE 320, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-761-4904 or via email at [email protected]
MarketBeat Community Rating for Aldeyra Therapeutics (NASDAQ ALDX)
MarketBeat's community ratings are surveys of what our community members think about Aldeyra Therapeutics and other stocks. Vote "Outperform" if you believe ALDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
